We’re developing a best-in-class portfolio of immune cell modulators to help dampen the inflammatory response and restore immune balance. Anaptys president and CEO Daniel Faga reflects on pipeline progress. #Q3Earnings $ANAB ir.anaptysbio.com/news-releases/…

#NEWS: We are thrilled to share that BioSpace has named AnaptysBio a Best Place to Work for 2024! This recognition is a tremendous honor and testament to all the incredible team members who shape our one-of-a-kind #companyculture. Learn more: ir.anaptysbio.com/news-releases/…

An estimated four in 10 people living with #RheumatoidArthritis (RA) do not achieve disease remission with current standard of care. Dr. Jonathan Graf of UCSF Rheumatology offers his perspective on the unmet needs in the community.

Hello, #ACR23! We’re thrilled to be in our hometown of San Diego for six full days of learning and meaningful engagement with fellow leaders in #Rheumatology and #LifeSciences. Conference attendees, learn about our poster presentations below. American College of Rheumatology

#ACR23 attendees: don’t miss your chance to learn about our ongoing research and work to support people living with #InflammatoryDisease, including RA. Visit our posters in the Poster Hall today through Tuesday.

#ICYMI: Last month, we hosted a virtual R&D event to discuss important updates on our PD-1 Agonist #MoncolonalAntibody for #RheumatoidArthritis and #UlcerativeColitis. Listen to the full recording: edge.media-server.com/mmc/p/82wr25ct/ $ANAB

Great connecting with friends old and new at #ACR23. While there’s still plenty of work ahead to address the needs of people living with #Rheumatic diseases, we’re inspired by the progress made to date.

We have recently welcomed six exceptional new colleagues to the Anaptys team. Learn about their roles below. #WeAreAnaptysBio

#NEWS: Today, we announced an exclusive license agreement for @Centessa’s blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio for the treatment of autoimmune and inflammatory diseases. Learn more: ir.anaptysbio.com/news-releases/…

Today, we’re spotlighting Tae Lee, an exceptional colleague who embodies our company’s core values and plays a key role in our ongoing work to deliver innovative immunology therapeutics. We’re so glad you’re on our team, Tae!

Thank you, Crohn's & Colitis Foundation, for joining us virtually during #CCAwarenessWeek and sharing how we can work together to better support the #IBD community. #WeAreAnaptysBio

We believe the PD-1 pathway may play a key role in the treatment of #UlcerativeColitis. Learn more here: bit.ly/3MHc6My #CCAwarenessWeek

From initiating #ClinicalTrials in multiple therapeutic areas to adding amazing new team members, we made significant progress in 2023. Learn about a few key milestones below. #WeAreAnaptysBio

Season’s greetings from Anaptys! Wishing you a joyous, peaceful holiday season. May 2024 bring new discoveries, breakthroughs, and continued progress toward a healthier future for all. #WeAreAnaptysBio

Today, we announced our #Q1 update. Catch up on our progress developing best-in-class immune cell modulators (ICMs) for patients living with heterogeneous, systemic autoimmune and inflammatory diseases. Learn more: ir.anaptysbio.com/news-releases/… #Q1Earnings $ANAB

Yesterday, we announced a $50 million capped non-recourse monetization with Sagard in exchange for additional Jemperli royalties. Proceeds from this transaction will further enable development of our best-in-class #ImmuneCellModulator portfolio: bit.ly/4bvsN7R $ANAB

Today, we announced our #Q2 earnings and provided an update on our work to develop immune cell modulators for patients living with #Autoimmune and #InflammatoryDiseases. Read our full announcement: bit.ly/46Hqxcw #Q2Earnings $ANAB

We’ve announced a $100 million equity offering, led by long-standing investor EcoR1 Capital, LLC, with participation from additional existing and new investors, including Sanofi. The offering is expected to close ~Aug. 15, 2024, subject to customary closing conditions. $ANAB